SB 623

Drug Profile

SB 623

Alternative Names: Modified bone marrow derived mesenchymal stem cells - SanBio; SB623

Latest Information Update: 03 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SanBio
  • Developer SanBio; Sumitomo Dainippon Pharma; Sunovion Pharmaceuticals; Teijin
  • Class Antidementias; Antiparkinsonians; Neuroprotectants; Stem cell therapies
  • Mechanism of Action Cell replacements; Nerve growth factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Brain injuries; Stroke
  • Preclinical Parkinson's disease; Retinal disorders; Spinal cord injuries
  • Research Alzheimer's disease

Most Recent Events

  • 01 Apr 2018 SanBio intends to file for regulatory approval of SB 623 for Brain injuries in Japan, in the fiscal year ending January 2020
  • 01 Apr 2018 SanBio completes enrolment in a phase II trial for Brain injuries in USA and Japan
  • 28 Feb 2018 Early research in Alzheimer's disease in USA before February 2018 (SanBio pipeline,February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top